Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03695861
Other study ID # CHUBX 2017/33
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 10, 2018
Est. completion date September 16, 2020

Study information

Verified date October 2020
Source University Hospital, Bordeaux
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The diagnosis of infectious endocarditis is not always easy and is based on several clinical and imaging arguments. Positron Emission Tomography - Computed Tomography (PET-CT) has been validated for endocarditis on prosthetic valves but few studies concern the native valves. The purpose of the study is to estimate the diagnostic sensitivity of [18F]-fluoro-2-deoxyglucose (18F-FDG) PET-CT in patients with endocarditis on native valves according to the European Society of Cardiology 2015 (ESC 2015) modified diagnostic criteria of infective endocarditis classified as definite at three months of follow-up (baseline test).


Description:

Infectious endocarditis remains a serious pathology with an intra-hospital mortality of between 15 and 30%. The prognosis of patients depends on the speed of diagnosis and the beginning of the appropriate treatment.

Currently, the diagnosis of endocarditis is based on the ESC 2015 modified criteria. Echocardiography techniques play a key role, but can be negative in 20% of endocarditis. 18F-FDG PET-CT showed promising results in the management of prosthetic valve endocarditis and / or stimulation material.

However, few studies have been carried out on the contribution of PET-CT in the diagnosis of endocarditis on native valves, with discordant results. But this is the majority of endocarditis (70% of cases).

A 18F-FDG PET-CT will be performed in all patients included in the study in addition to standard care for endocarditis, within 5 days of the beginning of their management in the university hospital center of Bordeaux after verification of inclusion and exclusion criteria and signature of consent.

The included patients will be reviewed at Month 3 during a consultation with the completion of a clinical examination, an electrocardiogram, a biological assessment and a transthoracic ultrasound.

Adverse events and serious adverse events will be collected throughout the study.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date September 16, 2020
Est. primary completion date September 16, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Any patient = 18 years treated at the university hospital center of Bordeaux for suspicion of infectious endocarditis on a native valve with a "definite" or "possible" diagnosis according to the ESC 2015 modified diagnostic criteria, agreeing to participate,

- Affiliated person or beneficiary of a social security scheme,

- Free, informed and written consent (no later than the day of inclusion and before any exam required by the research).

Exclusion Criteria:

- Patient with a vital failure (haemodynamic, respiratory or neurological instability), requiring treatment in the intensive care unit and / or urgent surgery incompatible with performing PET-CT,

- Pregnant or nursing woman,

- Patient who has already been treated for infective endocarditis within six months of enrollment,

- Patient who had cardiac surgery in the two months preceding inclusion,

- Patient who has previously been hypersensitive to fluorodeoxyglucose and / or excipients of the radiotracer,

- Patient unable to sign consent,

- Patient under legal protection,

- Women of childbearing age who do not benefit from effective contraception (HAS criteria),

- Patient in a period of relative exclusion from another research protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Whole-body 18F-FDG PET-CT scan
A 18F-FDG PET-CT will be performed within 5 days of the beginning of the patients care with infectious endocarditis at the University Hospital center of Bordeaux.

Locations

Country Name City State
France University hospital, Bordeaux Pessac

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity of the 18F-FDG PET-CT in the diagnosis of infectious endocarditis The reference test in this study will be a "definite diagnosis" of infectious endocarditis according to the ESC 2015 modified criteria at three months of follow-up, evaluated by a multidisciplinary committee in infectious endocarditis. This evaluation will be done blind to the results of the PET-CT of the study. The index test 18F-FDG PET-CT will have been performed at the initial phase of patient management. 3 month
See also
  Status Clinical Trial Phase
Recruiting NCT05547607 - Clinical and Diagnostic Features of Endocarditis
Completed NCT00750373 - Early Surgery Versus Conventional Treatment in Infective Endocarditis Phase 4
Recruiting NCT03690076 - Human Cardiac Mitochondria in Acute Endocarditis and Obesity
Terminated NCT01734694 - Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Phase 4
Terminated NCT00995384 - Cardiac Computed Tomography (CT) Scan Compared to Transesophageal Echocardiogram (TEE) in Endocarditis N/A
Completed NCT04309591 - Cytosorb Therapy in Cardiac Surgery
Recruiting NCT05142891 - Renal Tolerance of Amoxicillin and Cloxacillin Combination
Recruiting NCT05703022 - Early Exercise Training in Patients Following Heart Valve Surgery for Infective Endocarditis. N/A
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Completed NCT03377465 - Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis N/A
Recruiting NCT03892174 - Cytokine REmoval in CRitically Ill pAtients Requiring Surgical Therapy for Infective Endocarditis (RECReATE) N/A
Recruiting NCT02759978 - Individualized Diagnosis of Endocarditis and Its Therapy With a Focus on Infected Prosthetic materiAL
Completed NCT00709358 - Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections Phase 4
Terminated NCT03148756 - Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis Phase 2
Enrolling by invitation NCT05156437 - Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) Phase 4
Recruiting NCT06107309 - Suppressive Antibiotic Therapy for Endocarditis
Completed NCT02251262 - Diagnostic Accuracy of 18FDG-PET-CT for Pacing or Defibrillation Lead Infection N/A
Recruiting NCT03112356 - The Value of 99mTc-Leukoscan® Scintigraphy in the Diagnosis of Infectious Endocarditis on Surgical Materials Phase 4
Completed NCT01375257 - Partial Oral Treatment of Endocarditis Phase 4
Terminated NCT00590889 - Artificial Valve Endocarditis Reduction Trial N/A